GLP-1 / metabolic
Liraglutide
FDA-approvedVictoza, Saxenda · GLP-1 receptor agonist
Once-daily GLP-1 agonist, predecessor to semaglutide.
What it is
A daily GLP-1 analog with a fatty-acid modification for ~1-day duration; marketed as Victoza (T2D) and Saxenda (weight), now with generics.
How it works
GLP-1 agonism increases glucose-dependent insulin, suppresses glucagon, slows gastric emptying and reduces appetite.
Studied for
Glycemic control, weight management, CV risk reduction (LEADER).
Regulatory status
FDA-approved drug (generic available).
Safety
GI effects common; boxed thyroid C-cell tumor warning; pancreatitis and gallbladder cautions.
What the community reports about Liraglutide
Aggregated from real community discussions across social platforms and forums. Anecdotal and self-reported — not causal, not medical advice.
The original daily GLP-1. Liraglutide (Victoza/Saxenda) is one of the first-generation GLP-1 receptor agonists — part of the incretin class that's been on the market for roughly 20 years (starting with exenatide in 2005) before the newer weekly drugs like semaglutide. It's the older, shorter-acting predecessor in the same family, and like the rest of the class is now being studied for sleep apnea.
- Worked well for some — 34 lb in 6 months reported
- Original daily GLP-1; long market track record
Aggregated from public discussions and community forums, synthesized into themes and counts. Anecdotal and self-reported — not causal, not evidence a compound is safe or effective, not medical advice, and not a recommendation to use. No dosing shown.
Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.